22936 Federal Register / Vol. 87, No. 74 / Monday, April 18, 2022 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Advisory 

Council on Drug Abuse. 

The meeting will be held as a virtual 

meeting and is open to the public, as 

indicated below. Individuals who plan 

to view the virtual meeting and need 

special assistance or other reasonable 

accommodations to view the meeting, 

should notify the Contact Person listed 

below in advance of the meeting. The 

open session will be videocast and can 

be accessed from the NIH Videocasting 

and Podcasting website (http://

videocast.nih.gov/). 

A portion of the meeting will be 

closed to the public in accordance with 

the provisions set forth in sections 

552b(c)(4) and 552b(c)(6), title 5 U.S.C., 

as amended. The intramural programs 

and projects as well as the grant 

applications and/or contract proposals 

and the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with intramural 

programs and projects as well as the 

grant applications and/or contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council on Drug Abuse. 

Date: May 10, 2022. 

Closed: 11:00 a.m. to 12:15 p.m. 

Agenda: To review and evaluate grant 

applications. 

Closed: 12:15 p.m. to 12:45 p.m. 

Agenda: Report to Council from the Board 

of Scientific Counselors (BSC). 

Open: 1:15 p.m. to 4:45 p.m. 

Agenda: Presentations and other business 

of the Council. 

Place: National Institutes of Health, 

National Institute on Drug Abuse, 301 North 

Stonestreet Avenue, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Susan R.B. Weiss, Ph.D., 

Director, Division of Extramural Research, 

Office of the Director, National Institute on 

Drug Abuse, NIH, Three White Flint North, 

RM 09D08, 11601 Landsdown Street, 

Bethesda, MD 20852, 301–443–6480, sweiss@

nida.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

www.drugabuse.gov/NACDA/ 

NACDAHome.html, where an agenda and 

any additional information for the meeting 

will be posted when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.277, Drug Abuse Scientist 

Development Award for Clinicians, Scientist 

Development Awards, and Research Scientist 

Awards; 93.278, Drug Abuse National 

Research Service Awards for Research 

Training; 93.279, Drug Abuse and Addiction 

Research Programs, National Institutes of 

Health, HHS) 

Dated: April 12, 2022. 

Tyeshia M. Roberson-Curtis, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–08267 Filed 4–15–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Peter Soukas, J.D., 301–496–2644; 

peter.soukas@nih.gov. Licensing 

information and copies of the patent 

applications listed below may be 

obtained by communicating with the 

indicated licensing contact at the 

Technology Transfer and Intellectual 

Property Office, National Institute of 

Allergy and Infectious Diseases (NIAID), 

5601 Fishers Lane, Rockville, MD 

20852; tel. 301–496–2644. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of 

unpublished patent applications. 

SUPPLEMENTARY INFORMATION: 

Technology description follows: 

Expression of Prefusion-Stabilized 

Spike S Glycoprotein of SARS CoV–2 

From Avian Paramyxovirus Type 3 

(APMV3) 

Description of Technology: Severe 

acute respiratory syndrome coronavirus 

2 (SARS–CoV–2) emerged in 2019 as the 

causative agent of coronavirus disease 

2019 (COVID–19) and has created a 

pandemic and global crisis in public 

health. Vaccines for SARS–CoV–2 are 

increasingly available under emergency 

use authorizations; however, 

authorizations for use are currently 

limited to individuals five (5) years or 

older. They also involve intramuscular 

immunization, which does not directly 

stimulate local immunity in the 

respiratory tract, the primary site of 

SARS–CoV–2 infection, shedding and 

spread. Ideally, a vaccine should be 

effective as a single dose and should 

induce systemic and mucosal immunity 

with the ability to restrict SARS–CoV– 

2 infection and respiratory shedding. 

The application relates to a live virusvectored intranasal vaccine candidate to 

prevent infection and transmission of 

SARS–CoV–2. Avian paramyxovirus 

type 3 (APMV3) was used as a vaccine 

vector to express the spike (S) protein 

stabilized in prefusion conformation by 

six proline substitutions (APMV3/S– 

6P). The S protein was from the first 

available SARS–CoV–2 sequence. A lack 

of pre-existing immunity in humans and 

attenuation by host range restriction 

make APMV3 a vector of interest. 

Unlike avian paramyxovirus 1 

(Newcastle Disease Virus), APMV3 is 

not a significant pathogen in poultry. 

The APMV3/S–6P vaccine is expected 

to induce durable and broad systemic 

and respiratory mucosal immunity 

against SARS–CoV–2. In the hamster 

model, a single intranasal dose of 

APMV3/S–6P induced a strong serum 

neutralizing antibody response to the 

vaccine-matched SARS–CoV–2 isolate 

WA1, and a strong serum IgG and IgA 

response to S protein and its receptorbinding domain. Serum antibodies of 

APMV3/S–6P-immunized hamsters 

effectively neutralized SARS–CoV–2 of 

lineages B.1.1.7 (Alpha) and 

B.1.351(Beta). Immunized hamsters 

challenged with SARS–CoV–2, strain 

WA1, did not exhibit weight loss and 

lung inflammation, and SARS–CoV–2 

replication in the upper and lower 

respiratory tract was low or 

undetectable. Thus, a single intranasal 

dose of APMV3/S–6P fully protected 

hamsters from SARS–CoV–2 challenge, 

suggesting that APMV3/S–6P is suitable 

for clinical development. 

Based on experience with this and 

other live-attenuated virus-vectored 

vaccine candidates in previous clinical 

studies, the present candidate is 

anticipated to be well-tolerated in 

humans. The National Institute of 

Allergy and Infectious Diseases has 

extensive experience and capability in 

evaluating live-attenuated respiratory 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 74 / Monday, April 18, 2022 / Notices 22937 

virus vaccine candidates in pediatric 

clinical studies, and opportunity for 

collaboration exists. 

This technology is available for 

nonexclusive licensing for commercial 

development in accordance with 35 

U.S.C. 209 and 37 CFR part 404, as well 

as for further development and 

evaluation under a research 

collaboration. 

Potential Commercial Applications: 

• Viral diagnostics 

• Vaccine research 

Competitive Advantages: 

• Ease of manufacture 

• B cell and T cell activation 

• Low-cost vaccines 

• Intranasal administration/needle-free 

delivery 

Development Stage: 

• In vivo data assessment (animal) 

Inventors: Ursula Buchholz (NIAID), 

Shirin Munir (NIAID), Cyril Le Nouen 

(NIAID), Hongsu Park (NIAID), Cindy 

Luongo (NIAID), Peter Collins (NIAID). 

Intellectual Property: HHS Reference 

No. E–238–2020–0—U.S. Provisional 

Application No. 63/280,884, filed 

November 18, 2021. 

Licensing Contact: Peter Soukas, J.D., 

301–496–2644; peter.soukas@nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize for development of a 

vaccine for respiratory or other 

infections. For collaboration 

opportunities, please contact Peter 

Soukas, J.D., 301–496–2644; 

peter.soukas@nih.gov. 

Dated: April 12, 2022. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2022–08154 Filed 4–15–22; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Aging Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Aging Special Emphasis Panel; T Cells and 

Aging. 

Date: May 26, 2022. 

Time: 12:00 p.m. to 3:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institute on Aging, 

Gateway Building, 7201 Wisconsin Avenue, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Anita H. Undale, Ph.D., 

MD, Scientific Review Branch, National 

Institute on Aging, Gateway Building, Suite 

2W200, 7201 Wisconsin Avenue, Bethesda, 

MD 20892, (301) 827–7428, anita.undale@

nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.866, Aging Research, 

National Institutes of Health, HHS) 

Dated: April 12, 2022. 

Miguelina Perez, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2022–08206 Filed 4–15–22; 8:45 am] 

BILLING CODE 4140–01–P 

INSTITUTE OF AMERICAN INDIAN AND 

ALASKA NATIVE CULTURE AND ARTS 

DEVELOPMENT 

Request for Nominations to the Board 

of Trustees 

AGENCY: Institute of American Indian 

and Alaska Native Culture and Arts 

Development (aka Institute of American 

Indian Arts). 

ACTION: Notice; request for nominations. 

SUMMARY: The Board directs the 

Administration of the Institute of 

American Indian and Alaska Native 

Culture and Arts Development, 

including soliciting, accepting, and 

disposing of gifts, bequests, and other 

properties for the benefit of the Institute. 

The Institute provides scholarly study of 

and instruction in Indian art and culture 

and establishes programs which 

culminate in the awarding of degrees in 

the various fields of Indian art and 

culture. The Board consists of thirteen 

members appointed by the President of 

the United States, by and with the 

consent of the U.S. Senate, who are 

American Indians or persons 

knowledgeable in the field of Indian art 

and culture. This notice requests 

nominations to fill two expiring terms 

on the Board of Trustees. 

ADDRESSES: Institute of American Indian 

Arts, 83 Avan Nu Po Road, Santa Fe, 

New Mexico 87508. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Robert Martin, President, 505–424– 

2301. 

Dated: April 6, 2022. 

Robert Martin, 

President. 

[FR Doc. 2022–08264 Filed 4–15–22; 8:45 am] 

BILLING CODE 4312–W4–P 

DEPARTMENT OF THE INTERIOR 

[FWS–R4–ES–2022–N227; 

FVHC98220410150–XXX–FF04H00000] 

Deepwater Horizon Oil Spill Natural 

Resource Damage Assessment, 

Florida Trustee Implementation Group 

Draft Phase V.4 Florida Coastal Access 

Project: Restoration Plan and 

Supplemental Environmental 

Assessment 

AGENCY: Department of the Interior. 

ACTION: Notice of availability; request 

for public comments; announcement of 

webinar and in-person meeting. 

SUMMARY: In accordance with the Oil 

Pollution Act of 1990 (OPA), the 

National Environmental Policy Act of 

1969 (NEPA), the Final Programmatic 

Damage Assessment Restoration Plan 

and Final Programmatic Environmental 

Impact Statement (Final PDARP/PEIS), 

and Consent Decree, the Federal and 

State natural resource trustee agencies 

for the Florida Trustee Implementation 

Group (FL TIG) have prepared the Draft 

Phase V.4 Florida Coastal Access 

Project: Restoration Plan and 

Supplemental Environmental 

Assessment (Phase V.4 RP/SEA). The FL 

TIG is proposing a fourth phase of the 

Florida Coastal Access Project. The 

preferred alternative includes the 

acquisition of the Dickerson Bay parcel: 

A 114-acre undeveloped coastal 

inholding in Wakulla County, Florida, 

within the approved boundary of St. 

Marks National Wildlife Refuge (NWR). 

This would continue the process of 

restoring lost recreational use in the 

Florida Restoration Area resulting from 

the Deepwater Horizon (DWH) oil spill. 

We invite comments on the Draft Phase 

V.4 RP/SEA. 

DATES: 

Submitting Comments: We will 

consider public comments on the Draft 

Phase V.4 RP/SEA received on or before 

May 18, 2022. 

Public Meeting: The FL TIG will host 

a webinar on May 10, 2022, at 3 p.m. 

Eastern Time (ET), and an in-person 

public meeting on May 12 at 5:30 p.m. 


khammond on DSKJM1Z7X2PROD with NOTICES